Danish pharmaceutical giant Novo Nordisk gains significant access with the approval of its weight-loss drug Wegovy in China. This move grants Novo Nordisk entry into the world's second-largest economy, targeting a growing population facing obesity challenges. Key Considerations: Wegovy targets patients with a Body Mass Index (BMI) of 30 or higher alongside...
Novo Nordisk (NVO) hit the 1D MA50 (blue trend-line) again for the first time since December 18 2023 and after a long time it gives buy signals again. The correction came after the March 07 rejected at the top of the (dotted) Channel Up, following overbought 1D RSI levels before that for 2 weeks. That is a pattern consistent with all previous Higher High...
In the ever-evolving landscape of technological innovation, a new wave of AI computers is poised to revolutionize computation as we know it. With processors designed specifically for AI programs, these machines unlock a realm of possibilities for individuals, governments, and scientific organizations alike. At the forefront of this transformative wave is Danish...
Novo Nordisk ( NYSE:NVO ) made waves in the pharmaceutical industry as its stock skyrocketed to unprecedented heights following the announcement of groundbreaking results from its experimental oral weight-loss drug, amycretin. The drugmaker's innovative approach, which combines GLP-1 and amylin hormones, surpassed expectations by demonstrating remarkable efficacy...
The Big 4 Earnings Releases today (POSITIVE) ✅ Novo Nordisk ⬆️ ✅ Mastercard ⬆️ ⌛️ Qualcomm (released later today) ✅ Boston Scientific ⬆️ The chart shows expected & reported earnings & price action. IMO Mastercard looks particularly promising. NYSE:NVO NYSE:MA NASDAQ:QCOM NYSE:BSX
Novo Nordisk is emerging from a textbook volatility compression pattern (VCP) - the setup made famous by Mark Minervini. Notice the series of progressively shallower pullbacks from left to right as supply has been absorbed by buyers. NVO is a market-leading stock by all accounts. Shares are up 75% over the last twelve months with no signs of slowing down. This is...
Analyzing the options chain and the chart patterns of NVO Novo Nordisk prior to the earnings report this week, I would consider purchasing the $162.5 strike price Calls with an expiration date of 2023-8-18, for a premium of approximately $6.85. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking...
It seems NOVO is ending x in a corrective xyz of (4) Target 600 during april 2022 before further upside during the rest of the year
Is seems NOVO is about to finish a minor wave 2 now to continue higher with an impulse to 5 There should be a long way to go still and targets between 1000 and 1400 are in reach
Novo Nordisk is at a low point right now. It seems like they are getting support and could rise high very soon.
Another impulse done and dusted. Divergent, now looking out of steam. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore...
NOVONORDISK B A/S Long short days volume
My analysis of Novo Nordisk as of 6.12.2020 With the current recommendation for "buy" with my eyes (short term)
The last anaylsis of Novo Nordisk was successful at its prediction. Heres an updated one of where i see it in the short term future